Your browser doesn't support javascript.
BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design.
Tartof, Sara Y; Frankland, Timothy B; Puzniak, Laura; Slezak, Jeff M; Hong, Vennis; Takhar, Harpreet; Ogun, Oluwaseye A; Simmons, Sarah; Xie, Fagen; Zamparo, Joann; Ackerson, Bradley K; Jodar, Luis; McLaughlin, John M.
  • Tartof SY; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Frankland TB; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
  • Puzniak L; Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, Hawaii, USA.
  • Slezak JM; Pfizer Inc., Collegeville, Pennsylvania, USA.
  • Hong V; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Takhar H; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Ogun OA; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Simmons S; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Xie F; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Zamparo J; Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
  • Ackerson BK; Pfizer Inc., Collegeville, Pennsylvania, USA.
  • Jodar L; Southern California Permanente Medical Group, Harbor City, California, USA.
  • McLaughlin JM; Pfizer Inc., Collegeville, Pennsylvania, USA.
J Pediatric Infect Dis Soc ; 12(3): 177-179, 2023 Apr 18.
Article in English | MEDLINE | ID: covidwho-2222669
ABSTRACT
In a 11 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI 47-69] <3 months post-dose-two and 28% [8-43] after ≥3 months. A booster improved protection to 77% [53-88].
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Risk_factors_studies Topics: Vaccines / Variants Limits: Child / Humans Language: English Journal: J Pediatric Infect Dis Soc Year: 2023 Document Type: Article Affiliation country: Jpids

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Type of study: Risk_factors_studies Topics: Vaccines / Variants Limits: Child / Humans Language: English Journal: J Pediatric Infect Dis Soc Year: 2023 Document Type: Article Affiliation country: Jpids